Overview
Glucagon is a 29 amino acid hormone used as a diagnostic aid in radiologic exams to temporarily inhibit the movement of the gastrointestinal tract and to treat severe hypoglycemia. Glucagon raises blood sugar through activation of hepatic glucagon receptors, stimulating glycogenolysis and the release of glucose. Glucagon was granted FDA approval on 14 November 1960.
Indication
Glucagon is indicated as a diagnostic aid in radiologic exams to temporarily inhibit the movement of the gastrointestinal tract and to treat severe hypoglycemia.
Associated Conditions
- Severe Hypoglycemia
Clinical Trials
Title | Posted | Study ID | Phase | Status | Sponsor |
|---|---|---|---|---|---|
2025/05/23 | Phase 4 | Recruiting | |||
2025/03/12 | Not Applicable | Not yet recruiting | |||
2024/09/19 | Phase 1 | Recruiting | |||
2024/08/16 | Phase 1 | Not yet recruiting | |||
2024/02/09 | N/A | Recruiting | |||
2023/11/13 | Phase 1 | Withdrawn | |||
2023/07/25 | Phase 2 | Terminated | St. Olavs Hospital | ||
2023/02/13 | Phase 1 | Suspended | |||
2022/08/15 | Phase 1 | Recruiting | |||
2022/01/28 | N/A | Active, not recruiting |
FDA Drug Approvals
Approved Product | Manufacturer | NDC Code | Route | Strength | Effective Date |
|---|---|---|---|---|---|
| Xeris Pharmaceuticals, Inc. | 72065-141 | SUBCUTANEOUS | 1 mg in 0.2 mL | 9/26/2023 | |
| Xeris Pharmaceuticals, Inc. | 72065-140 | SUBCUTANEOUS | 1 mg in 0.2 mL | 9/26/2023 | |
| Xeris Pharmaceuticals, Inc. | 72065-130 | SUBCUTANEOUS | 0.5 mg in 0.1 mL | 9/26/2023 | |
| Eli Lilly and Company | 0002-6145 | NASAL | 3 mg in 1 1 | 8/16/2021 | |
| Xeris Pharmaceuticals, Inc. | 72065-121 | SUBCUTANEOUS | 1 mg in 0.2 mL | 9/26/2023 | |
| Healing Power Within Inc. | 51264-0001 | ORAL | 30 [hp_X] in 1 mL | 5/23/2025 | |
| Xeris Pharmaceuticals, Inc. | 72065-131 | SUBCUTANEOUS | 1 mg in 0.2 mL | 9/26/2023 | |
| Xeris Pharmaceuticals, Inc. | 72065-120 | SUBCUTANEOUS | 0.5 mg in 0.1 mL | 9/26/2023 | |
| Next Generation Health | 69192-0001 | ORAL | 30 [hp_X] in 1 mL | 5/22/2025 |
EMA Drug Approvals
Approved Product | Authorization Holder | Status | Issued Date |
|---|---|---|---|
Authorised | 2/11/2021 | ||
Authorised | 12/16/2019 |
HSA Drug Approvals
Approved Product | Manufacturer | Approval Number | Dosage Form | Strength | Approval Date |
|---|---|---|---|---|---|
| GLUCAGEN FOR INJECTION 1 mg/ml | SIN09070P | INJECTION, POWDER, FOR SOLUTION | 1mg/ml | 12/9/1996 |
NMPA Drug Approvals
Approved Product | Company | Approval Number | Drug Type | Dosage Form | Approval Date |
|---|---|---|---|---|---|
| Glucagon hydrochloride for Injection | 国药准字H20046036 | 化学药品 | 注射剂 | 4/9/2020 |
PPB Drug Approvals
Approved Product | Registration No. | Company | Licence No. | Strength | Registration Date |
|---|---|---|---|---|---|
| No PPB approvals found for this drug. | |||||
TGA Drug Approvals
Approved Product | ARTG ID | Sponsor | Registration Type | Status | Registration Date |
|---|---|---|---|---|---|
| GLUCAGEN HYPOKIT 1mg powder for injection vial with diluent syringe | 47105 | Medicine | A | 2/28/1994 |
Help Us Improve
Your feedback helps us provide better drug information and insights.